Cargando…
Overcoming Resistance to Drugs Targeting KRAS(G12C) Mutation
Activating KRAS mutations are present in 25% of human cancer. Although oncogenic Ras was deemed “undruggable” in the past, recent efforts led to the development of pharmacological inhibitors targeting the KRAS(G12C) mutant, which have shown promise in early clinical trials. The development of allele...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491749/ https://www.ncbi.nlm.nih.gov/pubmed/32939510 http://dx.doi.org/10.1016/j.xinn.2020.100035 |